Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 3/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 6/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570999 | 0.79 | TRIM24 (0.33) | BMPR1BBMPR1AACVRL1ACVR1GAA | |
| SCHEMBL12339193 | 0.78 | USP1 (0.38) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL14560231 | 0.75 | BMPR1B (0.35) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL18237516 | 0.74 | PIK3CD (0.31) | — | |
| SCHEMBL23932136 | 0.73 | BMPR1B (0.36) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL12339194 | 0.71 | GAA (0.32) | GAATDP1 | |
| SCHEMBL14560232 | 0.71 | BMPR1B (0.46) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL22402390 | 0.71 | USP1 (0.34) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL12339189 | 0.69 | BMPR1B (0.36) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL14560229 | 0.68 | BMPR1B (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8569426-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | ELAN PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8268935-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7794700-B2 | Multimeric VLA-4 antagonists comprising polymer moieties | ELAN PHARMACEUTICALS INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070021555-A1 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073788-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | BMPR1B 2347/4885BMPR1A 4415/4885ACVRL1 4654/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | BMPR1B 3117/4885BMPR1A 2498/4885ACVRL1 2754/4885 |
| US-20130018187-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | MANBA, OAT, PIGO | BMPR1B 2347/4885BMPR1A 4415/4885ACVRL1 4654/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | BMPR1B 3117/4885BMPR1A 2498/4885ACVRL1 2754/4885 |
| US-20120329807-A1 | Multimeric VLA-4 Antagonists Comprising Polymers Moieties | VCAM1, ICAM1, ITGB4 | BMPR1B 4086/4885BMPR1A 3264/4885ACVRL1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.